This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
RAC1 as a Therapeutic Target in Malignant Melanoma
Trends Cancer. 2020 Jun;6(6) :478-488
PMID: 32460002 PMCID: PMC7380552 URL: https://www.ncbi.nlm.nih.gov/pubmed/32460002
AbstractSmall GTPases of the RAS and RHO families are related signaling proteins that, when activated by growth factors or by mutation, drive oncogenic processes. While activating mutations in KRAS, NRAS, and HRAS genes have long been recognized and occur in many types of cancer, similar mutations in RHO family genes, such as RAC1 and RHOA, have only recently been detected as the result of extensive cancer genome-sequencing efforts and are linked to a restricted set of malignancies. In this review, we focus on the role of RAC1 signaling in malignant melanoma, emphasizing recent advances that describe how this oncoprotein alters melanocyte proliferation and motility and how these findings might lead to new therapeutics in RAC1-mutant tumors.
NotesCannon, Alexa C Uribe-Alvarez, Cristina Chernoff, Jonathan eng Review Trends Cancer. 2020 Jun;6(6):478-488. doi: 10.1016/j.trecan.2020.02.021. Epub 2020 Mar 18.